{"content":"<li class=\"n-box-item date-title\" data-end=\"1491278399\" data-start=\"1491192000\" data-txt=\"Sunday, December 22, 2019\">Monday, April  3, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3255276\" data-ts=\"1491255402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255276-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='green'>+35.4%</font>. <a href='https://seekingalpha.com/symbol/TISI' title='Team, Inc.'>TISI</a> <font color='green'>+3.9%</font>. <a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a> <font color='green'>+3.7%</font>. <a href='https://seekingalpha.com/symbol/CVGI' title='Commercial Vehicle Group, Inc.'>CVGI</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+2.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/RRTS' title='Roadrunner Transportation Systems, Inc.'>RRTS</a> <font color='red'>-7.9%</font>. <a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a> <font color='red'>-7.9%</font>. <a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a> <font color='red'>-5.4%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='red'>-4.8%</font>. <a href='https://seekingalpha.com/symbol/NMFC' title='New Mountain Finance'>NMFC</a> <font color='red'>-3.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255276\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$PRTK $TISI $CAR - After Hours Gainers / Losers https://seekingalpha.com/news/3255276-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3255276-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255268\" data-ts=\"1491253330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KATE\" target=\"_blank\">KATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255268-reuters-kate-spade-seeks-time-for-talks-after-coach-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Kate Spade seeks more time for talks after Coach bid</a></h4><ul>     <li>Kate Spade (NYSE:<a href='https://seekingalpha.com/symbol/KATE' title='Kate Spade & Company'>KATE</a>) <font color='red'>-6.2%</font> AH in response to a Reuters report that it may <a href=\"http://www.reuters.com/article/us-kate-spade-co-m-a-coach-idUSKBN1752ER\" target=\"_blank\">extend its pending sales process</a> by a few more weeks after receiving an offer <a href=\"https://seekingalpha.com/news/3253592-kate-spade-coach-deal-expected-around-corner\" target=\"_blank\">last week</a> from Coach (COH).</li>     <li>Michael Kors (KORS) also remains interested in KATE, although it has not been pursuing an acquisition as actively as  rival COH, according to the report.</li>     <li>KATE closed today's trade 1.8% lower at $22.80, giving it a ~$2.9B market cap; if the company manages to negotiate a sale, a deal likely would value it below that level, Reuters says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255268\" data-linked=\"Reuters: Kate Spade seeks more time for talks after Coach bid\" data-tweet=\"$KATE $KATE $TPR - Reuters: Kate Spade seeks more time for talks after Coach bid https://seekingalpha.com/news/3255268-reuters-kate-spade-seeks-time-for-talks-after-coach-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3255268-reuters-kate-spade-seeks-time-for-talks-after-coach-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255258\" data-ts=\"1491252371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDAP\" target=\"_blank\">EDAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255258-edap-q4-top-line-down-9-earnings-down-125-hifu-sales-up-39-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EDAP Q4 top line down 9%; earnings down 125%; HIFU sales up 39%; shares up 2% after hours</a></h4><ul><li>EDAP TMS SA (NASDAQ:<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a>) <a href=\"https://seekingalpha.com/pr/16789027-edap-achieves-63-percent-growth-hifu-revenue-2016\" target=\"_blank\">Q4 results</a> (&euro;M): Total Revenues: 10.7 (-9.3%); Medical Equipment Sales: 7.6 (-16.4%); HIFU Sales: 4.6 (+39.4%).</li><li>Net Loss: (1.3) (-125.0%); Loss/Share: (0.04) (-122.2%).</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours albeit on only 555 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255258\" data-linked=\"EDAP Q4 top line down 9%; earnings down 125%; HIFU sales up 39%; shares up 2% after hours\" data-tweet=\"$EDAP - EDAP Q4 top line down 9%; earnings down 125%; HIFU sales up 39%; shares up 2% after hours https://seekingalpha.com/news/3255258-edap-q4-top-line-down-9-earnings-down-125-hifu-sales-up-39-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3255258-edap-q4-top-line-down-9-earnings-down-125-hifu-sales-up-39-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255246\" data-ts=\"1491251058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWE\" target=\"_blank\">WWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255246-wwe-network-nears-2m-subscribers-after-wrestlemania\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WWE Network nears 2M subscribers after WrestleMania</a></h4><ul>   <li>Following an <a href=\"https://seekingalpha.com/news/3255110-wrestlemania-33-draws-75000-orlando\" target=\"_blank\">earlier update</a> on its flagship WrestleMania event, <a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a> announces that its WWE Network hit <a href=\"https://seekingalpha.com/pr/16789005-wwe-network-breaks-record-nearly-2-million-subscribers\" target=\"_blank\">1.95M total subscribers last night</a>.</li>    <li>That's up 7% from this time last year (after the 2016 WrestleMania).</li>    <li>The numbers include not only its best-ever total subscribers but also highs in domestic (up 4% to 1.45M) and international subs (up 15% to 497,000).</li>    <li>Paid subs hit 1.66M (14% gain; 1.24M domestic, 424,000 international).</li>    <li>The company also said subscribers watched 22.5M hours during \"WrestleMania Week,\" about 13 hours per subscriber, and that social media fan engagements were up 66% to 18M.</li>    <li>After hanging near flat late in the afternoon, in the past hour shares spiked down momentarily <font color='red'>as much as 7.5%</font> and ended up <font color='red'>off 1.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255246\" data-linked=\"WWE Network nears 2M subscribers after WrestleMania\" data-tweet=\"$WWE - WWE Network nears 2M subscribers after WrestleMania https://seekingalpha.com/news/3255246-wwe-network-nears-2m-subscribers-after-wrestlemania?source=tweet\" data-url=\"https://seekingalpha.com/news/3255246-wwe-network-nears-2m-subscribers-after-wrestlemania\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255231\" data-ts=\"1491250117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255231-sorrentos-anti-cea-car-t-candidate-shows-treatment-effect-in-cea-liver-cancer-patients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sorrento&#39;s anti-CEA CAR-T candidate shows treatment effect in CEA+ liver cancer patients but survival benefit barely ahead of Bayer&#39;s Stivarga and BSC; shares ease 8%</a></h4><ul><li>Thinly traded micro cap Sorrento Therapeutics (<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='red'>-7.6%</font>) moves lower on double normal volume in apparent response to its <a href=\"https://seekingalpha.com/pr/16788831-sorrento-therapeutics-anti-cea-car-t-demonstrates-promising-clinical-activity-safety-phase-ib\" target=\"_blank\">announcement </a>of early-stage results on its anti-CEA CAR-T candidate. The principal aim of the eight-subject study, HITM-SIR, was safety but secondary endpoints included response data. Participants were heavily pretreated with CEA-positive liver metastases.</li><li>Six patients completed the study, half had stable disease with decreases in the size of liver lesions ranging from 6 - 28%.</li><li>Mean overall survival &#40;OS&#41; as of March 28 was 7.5 months and median OS was 6.9 months. In comparison, median OS for regorafenib (Bayer's Stivarga) as monotherapy in chemo-refractory metastatic colorectal cancer patients is 6.4 months and 5 months for best supportive care &#40;BSC&#41;.</li><li>One patient out of six is still alive with no evidence of liver disease at almost 11 months of follow-up.</li><li>The data were presented at the American Association of Cancer Research Annual Meeting in Washington, DC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255231\" data-linked=\"Sorrento&#39;s anti-CEA CAR-T candidate shows treatment effect in CEA+ liver cancer patients but survival benefit barely ahead of Bayer&#39;s Stivarga and BSC; shares ease 8%\" data-tweet=\"$SRNE - Sorrento&#39;s anti-CEA CAR-T candidate shows treatment effect in CEA+ liver cancer patients but survival benefit barely ahead of Bayer&#39;s Stivarga and BSC; shares ease 8% https://seekingalpha.com/news/3255231-sorrentos-anti-cea-car-t-candidate-shows-treatment-effect-in-cea-liver-cancer-patients?source=tweet\" data-url=\"https://seekingalpha.com/news/3255231-sorrentos-anti-cea-car-t-candidate-shows-treatment-effect-in-cea-liver-cancer-patients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255215\" data-ts=\"1491248598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255215-eros-international-extends-revolver-works-refinancing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros International extends revolver as it works refinancing</a></h4><ul>   <li>After <font color='red'>falling 16.2%</font> overall since a March 9 GeoInvesting <a href=\"https://seekingalpha.com/news/3249990-eros-responds-short-report-postpones-bond-offering\" target=\"_blank\">short report</a> that raised chatter about liquidity concerns, India film producer Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) says it has <a href=\"https://seekingalpha.com/pr/16788096-eros-international-extends-revolving-credit-facility\" target=\"_blank\">extended the maturity</a> of its $85M revolving credit facility.</li>    <li>The maturity has been pushed out from April 1, 2017 to Sept. 30, 2017. It's also working on \"multiple long-term refinancing options\" to replace the revolver.</li>    <li>\"The company&rsquo;s long term shareholders continue to stand in support,\" Eros says, pointing to strong fundamentals including its new release slate, its back catalog and growth in new markets such as China.</li>    <li>Shares have turned for the worse again this afternoon, <font color='red'>-3.9%</font> to drop below the $10 mark.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255215\" data-linked=\"Eros International extends revolver as it works refinancing\" data-tweet=\"$EROS - Eros International extends revolver as it works refinancing https://seekingalpha.com/news/3255215-eros-international-extends-revolver-works-refinancing?source=tweet\" data-url=\"https://seekingalpha.com/news/3255215-eros-international-extends-revolver-works-refinancing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255206\" data-ts=\"1491245755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255206-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> COOL <font color='green'>+23%</font>. DRAM <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck Mobilisa, Inc.'>IDN</a> <font color='green'>+9%</font>.</li><li><b>Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RESN' title='Resonant'>RESN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/QTNA' title='Quantenna Communications'>QTNA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255206\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$PTE $USAU $YGE - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3255206-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3255206-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255194\" data-ts=\"1491242492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255194-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TDW' title='Tidewater, Inc.'>TDW</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/BIOA' title='BioAmber'>OTC:BIOA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/MFCB' title='MFC Bancorp Ltd.'>MFCB</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255194\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$ESES-OLD $AU $HMY - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3255194-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3255194-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255187\" data-ts=\"1491241551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PNRA\" target=\"_blank\">PNRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255187-baird-recommends-selling-panera-bread-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird recommends selling the Panera Bread news</a></h4><ul> <li>Baird recommends that investors take profit on their long position in Panera Bread (NASDAQ:<a href='https://seekingalpha.com/symbol/PNRA' title='Panera Bread Company'>PNRA</a>). The firm rates a buyout as a lower probability than the company moving forward on its own.</li> <li>Panera is <font color='green'>8.07% higher</font> on the day and is up 39% YTD.</li> <li>Source: Bloomberg</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3255155-panera-bread-soars-sale-talk\" target=\"_blank\">Panera Bread soars on sale talk</a> (April 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255160-starbucks-said-interested-panera\" target=\"_blank\">Starbucks said to be interested in Panera</a> (April 3)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255187\" data-linked=\"Baird recommends selling the Panera Bread news\" data-tweet=\"$PNRA - Baird recommends selling the Panera Bread news https://seekingalpha.com/news/3255187-baird-recommends-selling-panera-bread-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3255187-baird-recommends-selling-panera-bread-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255184\" data-ts=\"1491240840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255184-elon-musk-frisky-tesla-52-week-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elon Musk frisky with Tesla at 52-week high</a></h4><ul> <li>Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+5.5%</font>) CEO Elon Musk is paying attention to his company's share price after Q1 deliveries brought in new buyers.</li> <li>\"Stormy weather in Shortville ...,\" <a href=\"https://twitter.com/elonmusk/status/848935705057280001\" target=\"_blank\">tweets</a> Musk.</li> <li>Several Wall Street firms are out backing their prior ratings on Tesla after the update, but let's take a look at a new voice in the Tesla debate. Consumer Edge analyst James Albertine says Model X deliveries were significantly higher than anticipated, but warns that more investment will be needed for sales and charging infrastructure. Albertine notes that ~4,650 vehicles were in transit at the end of Q1 which will end up being counted as Q2 deliveries. Consumer Edge has Tesla slotted at Overweight with a $300 price target.</li> <li>Tesla cruised past its 52-week today on heavy volume, trading as high as $294.49.</li><li><a href=\"http://www.nasdaq.com/symbol/tsla/short-interest\" target=\"_blank\">Tesla Nasdaq short interest report</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3255184\" data-linked=\"Elon Musk frisky with Tesla at 52-week high\" data-tweet=\"$TSLA - Elon Musk frisky with Tesla at 52-week high https://seekingalpha.com/news/3255184-elon-musk-frisky-tesla-52-week-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3255184-elon-musk-frisky-tesla-52-week-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>152&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255183\" data-ts=\"1491240412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXAS\" target=\"_blank\">EXAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255183-unitedhealth-not-sold-on-fecal-dna-testing-for-crc-screening-exact-sciences-slips-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealth not sold on fecal DNA testing for CRC screening; Exact Sciences slips 1%</a></h4><ul><li>Exact Sciences (<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a> <font color='red'>-1.3%</font>) was down as much as&nbsp;<font color='red'>3%</font>&nbsp;earlier in the session on the news that insurer UnitedHealth (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+0.7%</font>) will not cover its Cologuard colorectal cancer &#40;CRC&#41;&nbsp;screening test saying fecal DNA testing for CRC screening/monitoring is \"unproven and not medically necessary.\" The non-coverage ruling went into effect April 1.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3255183\" data-linked=\"UnitedHealth not sold on fecal DNA testing for CRC screening; Exact Sciences slips 1%\" data-tweet=\"$EXAS $EXAS $UNH - UnitedHealth not sold on fecal DNA testing for CRC screening; Exact Sciences slips 1% https://seekingalpha.com/news/3255183-unitedhealth-not-sold-on-fecal-dna-testing-for-crc-screening-exact-sciences-slips-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3255183-unitedhealth-not-sold-on-fecal-dna-testing-for-crc-screening-exact-sciences-slips-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>212&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255178\" data-ts=\"1491238994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TZOO\" target=\"_blank\">TZOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255178-travelzoo-shutting-search-business-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Travelzoo shutting search business; shares up 2%</a></h4><ul><li>Part of a strategy to focus on the global Travelzoo (<a href='https://seekingalpha.com/symbol/TZOO' title='Travelzoo Inc'>TZOO</a> <font color='green'>+2.1%</font>) brand, the company at the end of March <a href=\"https://seekingalpha.com/filing/3486122\" target=\"_blank\">discontinued its </a>search business, consisting of Fly.com and SuperSearch.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255178\" data-linked=\"Travelzoo shutting search business; shares up 2%\" data-tweet=\"$TZOO - Travelzoo shutting search business; shares up 2% https://seekingalpha.com/news/3255178-travelzoo-shutting-search-business-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3255178-travelzoo-shutting-search-business-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255176\" data-ts=\"1491238987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPSEF\" target=\"_blank\">IPSEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255176-ipsen-completes-purchase-of-merrimack-assets-mack-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ipsen completes purchase of Merrimack assets; MACK up 4%</a></h4><ul><li>Ipsen (<a href='https://seekingalpha.com/symbol/IPSEF' title='Ipsen S.A.'>OTCPK:IPSEF</a>) <a href=\"https://seekingalpha.com/pr/16788674-ipsen-completes-acquisition-onivyde-irinotecan-liposome-injection-additional-oncology-assets\" target=\"_blank\">finalizes</a> its acquisition of ONIVYDE (irinotecan liposome injection) and other oncology assets from Merrimack Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='green'>+3.9%</font>).</li><li>Under the terms of the deal, Ipsen paid Merrimack $575M upfront and will pay up to $450M in milestones.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254522-merrimack-shareholders-back-asset-sale-ipsen-deal-close-shortly\" target=\"_blank\">Merrimack shareholders back asset sale to Ipsen, deal to close shortly</a> (March 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3255176\" data-linked=\"Ipsen completes purchase of Merrimack assets; MACK up 4%\" data-tweet=\"$IPSEF $IPSEF $MACK - Ipsen completes purchase of Merrimack assets; MACK up 4% https://seekingalpha.com/news/3255176-ipsen-completes-purchase-of-merrimack-assets-mack-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3255176-ipsen-completes-purchase-of-merrimack-assets-mack-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255179\" data-ts=\"1491238867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAIS\" target=\"_blank\">ZAIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255179-financials-top-5-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5  Losers as of 1:00 PM</a></h4><ul>     <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FNBC' title='First NBC Bank Holding Company'>OTC:FNBC</a> <font color='red'>-8%</font>. WAC <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255179\" data-linked=\"Financials - Top 5  Losers as of 1:00 PM\" data-tweet=\"$ZAIS $ZAIS $ONDK - Financials - Top 5 Losers as of 1:00 PM https://seekingalpha.com/news/3255179-financials-top-5-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3255179-financials-top-5-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255173\" data-ts=\"1491238369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255173-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+52%</font>. <a href='https://seekingalpha.com/symbol/NVCR' title='NovoCure'>NVCR</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a> <font color='green'>+40%</font>. DRAM <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/JOB' title='GEE Group, Inc.'>JOB</a> <font color='green'>+25%</font>. COOL <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/CALI' title='China Auto Logistics Inc.'>OTC:CALI</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+16%</font>. EBIO <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/XENE' title='Xenon Pharmaceuticals'>XENE</a>&nbsp;<font color='green'>+11%</font></li><li><b>Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='red'>-10%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics'>LPTX</a>&nbsp;<font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a>&nbsp;<font color='red'>-9%</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3255173\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CYCC $NVCR $STDY - Midday Gainers / Losers https://seekingalpha.com/news/3255173-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3255173-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255167\" data-ts=\"1491237356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAS\" target=\"_blank\">OAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255167-oasis-petroleum-upgraded-bmo-on-sustainable-growth-model\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasis Petroleum upgraded at BMO on more sustainable growth model</a></h4><ul>     <li>Oasis Petroleum (<a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='red'>-1.9%</font>) is lower even after BMO&nbsp;Capital <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9248497/why-oasis-petroleum-is-a-story-of-improving-fundamentals\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform with an $18 price target, citing improving fundamentals and attractive valuation following a recent decline.</li>     <li>BMO says OAS has become a pure-play Bakken producer that has improved returns in a manner that allows for &ldquo;a more sustainable growth model,&rdquo; and its debt-adjusted growth measures and cash-on-cash returns now appear more competitive.</li>     <li>The gap between capital spending and cash flow is expected to turn positive in 2018, and OAS seems to be posting among the highest recycle ratios in the group, the firm also says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255167\" data-linked=\"Oasis Petroleum upgraded at BMO on more sustainable growth model\" data-tweet=\"$OAS - Oasis Petroleum upgraded at BMO on more sustainable growth model https://seekingalpha.com/news/3255167-oasis-petroleum-upgraded-bmo-on-sustainable-growth-model?source=tweet\" data-url=\"https://seekingalpha.com/news/3255167-oasis-petroleum-upgraded-bmo-on-sustainable-growth-model\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255164\" data-ts=\"1491236658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RETA\" target=\"_blank\">RETA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255164-reata-pharma-closes-35m-loan-to-support-clinical-development-activities-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reata Pharma closes $35M loan to support clinical development activities; shares up 2%</a></h4><ul><li>Reata Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color='green'>+1.5%</font>) inks a $35M loan and security <a href=\"https://seekingalpha.com/pr/16787831-reata-pharmaceuticals-inc-secures-35-million-term-loan-facility\" target=\"_blank\">agreement </a>with Oxford Finance LLC and Silicon Valley Bank. Proceeds will support its clinical trials for bardoxolone and omavaloxolone.</li><li>The first tranche of $20M was funded on March 31. The remaining $15M tranche will be available from July 1 until March 31, 2018.</li><li>The interest rate is the sum of 7.4% plus the greater of 0.75% or the 30-day U.S. dollar LIBOR, not to exceed a total of 10.15%. An additional fee of 2.95% will be due when the principal is paid is paid in full (loan is due on March 1, 2022).</li></ul><div class=\"tiny-share-widget\" data-id=\"3255164\" data-linked=\"Reata Pharma closes $35M loan to support clinical development activities; shares up 2%\" data-tweet=\"$RETA - Reata Pharma closes $35M loan to support clinical development activities; shares up 2% https://seekingalpha.com/news/3255164-reata-pharma-closes-35m-loan-to-support-clinical-development-activities-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3255164-reata-pharma-closes-35m-loan-to-support-clinical-development-activities-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255163\" data-ts=\"1491236521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANET\" target=\"_blank\">ANET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255163-arista-dips-stifel-cuts-to-hold-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arista dips as Stifel cuts to Hold on valuation</a></h4><ul>   <li>Arista Networks (NYSE:<a href='https://seekingalpha.com/symbol/ANET' title='Arista Networks, Inc.'>ANET</a>) is <font color='red'>off 1.7%</font> today, pulling off recent all-time highs, as Stifel Nicolaus cuts to Hold following a solid year for the stock price.</li>    <li>Arista shares are up 8% over the past month, up 33.5% over the past three, and up 52.4% over the past six months and have more than doubled in the past year.</li>    <li>The stock's now at the high end of its historical range on enterprise value to EBITDA, Stifel notes, at around 17 times, and at more than five times enterprise value to sales.</li>    <li>The stock's still well positioned against competitors, notes analyst Aaron Rakers, who's raised the firm's price target on Arista to $135 from $130, implying about 3.8% upside from today's price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255163\" data-linked=\"Arista dips as Stifel cuts to Hold on valuation\" data-tweet=\"$ANET - Arista dips as Stifel cuts to Hold on valuation https://seekingalpha.com/news/3255163-arista-dips-stifel-cuts-to-hold-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3255163-arista-dips-stifel-cuts-to-hold-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255161\" data-ts=\"1491236454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255161-consumer-top-gainers-losers-of-12-20-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:20 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MPX' title='Marine Products Corporation'>MPX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AXL' title='American Axle & Manufacturing Holdings, Inc.'>AXL</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/THRM' title='Gentherm Incorporated'>THRM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255161\" data-linked=\"Consumer - Top Gainers / Losers as of 12:20 pm\" data-tweet=\"$SNAK $MPX $AXL - Consumer - Top Gainers / Losers as of 12:20 pm https://seekingalpha.com/news/3255161-consumer-top-gainers-losers-of-12-20-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3255161-consumer-top-gainers-losers-of-12-20-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255160\" data-ts=\"1491236220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBUX\" target=\"_blank\">SBUX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255160-starbucks-said-to-be-interested-in-panera\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starbucks said to be interested in Panera</a></h4><ul> <li>Jim Cramer says on CNBC that Starbucks (<a href='https://seekingalpha.com/symbol/SBUX' title='Starbucks Corporation'>SBUX</a> <font color='red'>-0.3%</font>) is the party interested in acquiring Panera Bread (<a href='https://seekingalpha.com/symbol/PNRA' title='Panera Bread Company'>PNRA</a> <font color='green'>+9.6%</font>).</li> <li>Bloomberg posted a story within the last half hour that indicated Panera would work with advisors in evaluating an offer it received.</li> <li>Neither company has confirmed the reports.</li> <li>Shares of Panera were halted by the Nasdaq for volatility.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3255155-panera-bread-soars-sale-talk\" target=\"_blank\">Panera Bread soars on sale talk</a> (April 3)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255160\" data-linked=\"Starbucks said to be interested in Panera\" data-tweet=\"$SBUX $SBUX $PNRA - Starbucks said to be interested in Panera https://seekingalpha.com/news/3255160-starbucks-said-to-be-interested-in-panera?source=tweet\" data-url=\"https://seekingalpha.com/news/3255160-starbucks-said-to-be-interested-in-panera\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255159\" data-ts=\"1491236052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVTA\" target=\"_blank\">NVTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255159-invitae-teams-up-alnylam-to-provide-testing-for-rare-gene-disorder-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Invitae teams up with Alnylam to provide testing for rare gene disorder; shares ahead 4%</a></h4><ul><li>Invitae (<a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a> <font color='green'>+3.7%</font>) perks up on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16787887-invitae-announces-new-partnership-alnylam-pharmaceuticals-provide-ttr-gene-testing-patients\" target=\"_blank\">announcement </a>of a partnership with Alnylam (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='red'>-0.9%</font>) to provided genetic testing for hereditary ATTR amyloidosis, a rare inherited and life-threatening disorder that causes accumulation of misfolded proteins in cells due to a mutation in the TTR gene.</li><li>The service, called Alnylam Act, is aimed at encouraging early genetic testing to aid in the prompt diagnosis of the disease. Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255159\" data-linked=\"Invitae teams up with Alnylam to provide testing for rare gene disorder; shares ahead 4%\" data-tweet=\"$NVTA $NVTA $ALNY - Invitae teams up with Alnylam to provide testing for rare gene disorder; shares ahead 4% https://seekingalpha.com/news/3255159-invitae-teams-up-alnylam-to-provide-testing-for-rare-gene-disorder-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3255159-invitae-teams-up-alnylam-to-provide-testing-for-rare-gene-disorder-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255157\" data-ts=\"1491235843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RRTS\" target=\"_blank\">RRTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255157-roadrunner-transportation-jumps-5-on-activist-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roadrunner Transportation jumps 5% on activist stake</a></h4><ul><li>Elliott Associates <a href=\"https://seekingalpha.com/symbol/RRTS/key-data/filings\" target=\"_blank\">discloses a </a>3.3M share, or 8.6% stake in Roadrunner Transportation (<a href='https://seekingalpha.com/symbol/RRTS' title='Roadrunner Transportation Systems, Inc.'>RRTS</a> <font color='green'>+5.4%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3255157\" data-linked=\"Roadrunner Transportation jumps 5% on activist stake\" data-tweet=\"$RRTS - Roadrunner Transportation jumps 5% on activist stake https://seekingalpha.com/news/3255157-roadrunner-transportation-jumps-5-on-activist-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3255157-roadrunner-transportation-jumps-5-on-activist-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255155\" data-ts=\"1491235620\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PNRA\" target=\"_blank\">PNRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255155-panera-bread-soars-on-sale-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Panera Bread soars on sale talk</a></h4><ul> <li>Panera Bread (NASDAQ:<a href='https://seekingalpha.com/symbol/PNRA' title='Panera Bread Company'>PNRA</a>)&nbsp;<font color='green'>spikes 8%</font>&nbsp;after Bloomberg reports that the company is exploring a possible sale after hearing from an interested party.</li> <li>Shares of Panera just hit an all-time high of $290.00.</li> <li>The story is still developing.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3255155\" data-linked=\"Panera Bread soars on sale talk\" data-tweet=\"$PNRA - Panera Bread soars on sale talk https://seekingalpha.com/news/3255155-panera-bread-soars-on-sale-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3255155-panera-bread-soars-on-sale-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255154\" data-ts=\"1491235317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORLY\" target=\"_blank\">ORLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255154-auto-parts-stocks-head-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto parts stocks head lower</a></h4><ul> <li>O'Reilly Automotive Group (<a href='https://seekingalpha.com/symbol/ORLY' title='O&#39;Reilly Automotive, Inc.'>ORLY</a> <font color='red'>-5.5%</font>) trades lower after Cleveland Research lowers the retailer to Neutral from Buy, citing DIY pressure on near-term sales.</li> <li>The firm also drops AutoZone (<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc'>AZO</a> <font color='red'>-3.4%</font>) to Neutral on the same concerns.</li> <li>Advance Auto Parts (<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color='red'>-2.9%</font>) and Geniune Parts (<a href='https://seekingalpha.com/symbol/GPC' title='Genuine Parts Company'>GPC</a> <font color='red'>-2.4%</font>) are also trailing off on a day that automakers are reporting weak tallies for March U.S. sales and an alarming forecast from Morgan Stanley on used car prices is generating some attention.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3255147-auto-retailers-tripped-pricing-concerns\" target=\"_blank\">Auto retailers tripped up by pricing concerns</a> (April 3)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255154\" data-linked=\"Auto parts stocks head lower\" data-tweet=\"$ORLY $ORLY $AZO - Auto parts stocks head lower https://seekingalpha.com/news/3255154-auto-parts-stocks-head-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3255154-auto-parts-stocks-head-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255147\" data-ts=\"1491234552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPI\" target=\"_blank\">GPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255147-auto-retailers-tripped-up-pricing-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto retailers tripped up by pricing concerns</a></h4><ul> <li>Auto retailers are sharply lower after a downbeat outlook from Morgan Stanley on used auto car prices catches some attention.</li> <li>Notably lower are Group 1 Automotive (<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a> <font color='red'>-5%</font>), CarMax (<a href='https://seekingalpha.com/symbol/KMX' title='CarMax Group'>KMX</a> <font color='red'>-5.1%</font>), Asbury Automotive Group (<a href='https://seekingalpha.com/symbol/ABG' title='Asbury Automotive Group, Inc.'>ABG</a> <font color='red'>-3.8%</font>), AutoNation (<a href='https://seekingalpha.com/symbol/AN' title='AutoNation Inc'>AN</a> <font color='red'>-3.9%</font>), Lithia Motors (<a href='https://seekingalpha.com/symbol/LAD' title='Lithia Motors, Inc.'>LAD</a> <font color='red'>-3.9%</font>), Sonic Automotive (<a href='https://seekingalpha.com/symbol/SAH' title='Sonic Automotive Inc.'>SAH</a> <font color='red'>-3%</font>) and Penske Automotive Group (<a href='https://seekingalpha.com/symbol/PAG' title='Penske Automotive Group, Inc.'>PAG</a> <font color='red'>-2.3%</font>).</li> <li>SA users are already discussing the implications of a sharp drop in used auto prices&nbsp;<a href=\"https://seekingalpha.com/news/3254924-sinking-feeling-used-car-market\" target=\"_blank\">here</a>&nbsp;(Sinking Feeling in the Used Car Market) and  <a href=\"https://seekingalpha.com/news/3255115-used-car-prices-look\" target=\"_blank\">here</a>&nbsp;(Used Car Prices - Look Out Below).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3255147\" data-linked=\"Auto retailers tripped up by pricing concerns\" data-tweet=\"$GPI $GPI $KMX - Auto retailers tripped up by pricing concerns https://seekingalpha.com/news/3255147-auto-retailers-tripped-up-pricing-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3255147-auto-retailers-tripped-up-pricing-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255148\" data-ts=\"1491234551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSIX\" target=\"_blank\">PSIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255148-power-solutionsplus-15-closes-deal-weichai-america\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Power Solutions +15% as it closes deal with Weichai America</a></h4><ul>     <li>Power Solutions International (<a href='https://seekingalpha.com/symbol/PSIX' title='Power Solutions International, Inc.'>OTCPK:PSIX</a> <font color='green'>+14.8%</font>) soars after saying it <a href=\"https://seekingalpha.com/pr/16788170-power-solutions-international-announces-closing-strategic-investment-collaboration-agreement\" target=\"_blank\">closed a share purchase agreement</a> with Weichai America, which will invest $60M in the company.</li><li>The two companies also enter into a strategic collaboration agreement in which they will work together to accelerate market opportunities for their respective product lines across various geographic and end user segments.</li><li>Shares have surged more than 80% since Weichai America first announced its commitment <a href=\"https://seekingalpha.com/news/3253693-power-solutions-plus-54-percent-chinese-firm-commits-60m-investment\" target=\"_blank\">a week ago</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255148\" data-linked=\"Power Solutions +15% as it closes deal with Weichai America\" data-tweet=\"$PSIX - Power Solutions +15% as it closes deal with Weichai America https://seekingalpha.com/news/3255148-power-solutionsplus-15-closes-deal-weichai-america?source=tweet\" data-url=\"https://seekingalpha.com/news/3255148-power-solutionsplus-15-closes-deal-weichai-america\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255144\" data-ts=\"1491233903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255144-treasury-yields-slip-banks-and-small-caps-lead-market-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasury yields slip further; banks and small-caps lead market lower</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3255102-employment-lifts-ism-manufacturing-index-higher\" target=\"_blank\">The ISM Manufacturing Index</a> remained strong, edging down inline with expectations to 57.2 in March from 57.7 previously. New Orders of 64.5 vs. 65.1 in February; Production 57.6 vs. 57.6; Employment 58.9 vs. 54.2; Prices 70.5 vs. 68.0.</li><li>The 10-year Treasury yield, nevertheless, continues to head lower, down five basis points this morning to 2.33%. Swing players will take note that that the yield has simply returned to the bottom of the 2.30-2.60% channel it's been in since shortly after Nov. 9. Might be time again to sell ahead of Friday's employment report? <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+1%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-2%</font></li><li>The Dow, S&amp;P 500, and Nasdaq are all&nbsp;<font color='red'>down about 0.5%</font>, but the Russell 2000 is&nbsp;<font color='red'>lower by 1.1%</font>. Lit up most red is the banking sector, with the <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> and <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> each<font color='red'> off by roughly 1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255144\" data-linked=\"Treasury yields slip further; banks and small-caps lead market lower\" data-tweet=\"$TLT $TBT $KBE - Treasury yields slip further; banks and small-caps lead market lower https://seekingalpha.com/news/3255144-treasury-yields-slip-banks-and-small-caps-lead-market-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3255144-treasury-yields-slip-banks-and-small-caps-lead-market-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255133\" data-ts=\"1491232069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255133-coupa-softwareminus-1_6-after-filing-for-80m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software -1.6% after filing for $80M share offering</a></h4><ul>   <li>Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>) is <font color='red'>off 1.6%</font> after filing to <a href=\"https://seekingalpha.com/filing/3485420\" target=\"_blank\">offer up to $80M in shares</a>.</li>    <li>Some shares will be sold by existing stockholders while another portion will be sold by the company.</li>    <li>But it hasn't yet determined the allocation of shares sold between existing stockholders and the company. It won't receive proceeds from shares sold by existing stockholders.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255133\" data-linked=\"Coupa Software -1.6% after filing for $80M share offering\" data-tweet=\"$COUP - Coupa Software -1.6% after filing for $80M share offering https://seekingalpha.com/news/3255133-coupa-softwareminus-1_6-after-filing-for-80m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3255133-coupa-softwareminus-1_6-after-filing-for-80m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255131\" data-ts=\"1491231823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUO\" target=\"_blank\">CUO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255131-continental-materials-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Continental Materials reports Q4 results</a></h4><ul><li>Continental Materials (NYSEMKT:<a href='https://seekingalpha.com/symbol/CUO' title='Continental Materials Corp'>CUO</a>): Q4 EPS of $0.20</li><li>Revenue of $36.99M (+5.3% Y/Y)</li><li>Shares <font color='green'>+3.66%</font>.</li><li><a href='https://seekingalpha.com/pr/16788620-continental-materials-corporation-reports-audited-2016-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3255131\" data-linked=\"Continental Materials reports Q4 results\" data-tweet=\"$CUO - Continental Materials reports Q4 results https://seekingalpha.com/news/3255131-continental-materials-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3255131-continental-materials-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255099\" data-ts=\"1491231607\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255099-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/NVCR' title='NovoCure'>NVCR</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+44%</font>. <a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a> <font color='green'>+14%</font>. EBIO <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255099\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$NVCR $CYCC $STDY - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3255099-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3255099-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255125\" data-ts=\"1491230633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYCC\" target=\"_blank\">CYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255125-cyclacels-next-gen-cdk-inhibitor-cyc065-shows-anti-tumor-effect-in-preclinical-testing-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cyclacel&#39;s next gen CDK inhibitor CYC065 shows anti-tumor effect in preclinical testing; shares ahead 41%</a></h4><ul><li>Thinly traded nano cap Cyclacel Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+41.3%</font>) jumps on a healthy 40x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16787595-cyclacels-second-generation-cdk2-9-inhibitor-cyc065-elicits-marked-antineoplastic-effects\" target=\"_blank\">announcement </a>of positive preclinical data on pipeline candidate CYC065, its next-generation cyclin-dependent kinase &#40;CDK&#41; 2/9 inhibitor. The data were presented at the American Association for Cancer Research Annual Meeting in Washington, DC.</li><li>The results showed that CYC065 significantly inhibited growth, triggered apoptosis and induced anaphase catastrophe in mouse and human lung cancer cells with known metastatic potential.</li><li>CEO Spiro Rombotis says, \"This study adds to the growing evidence of the value of CDK inhibition as an approach to treating cancer. CYC065 is in a Phase 1, first-in-human trial to evaluate safety, tolerability and pharmacokinetics in patients with solid tumors. The trial is at an expanded sixth dose escalation level with the objective of determining maximum tolerated dose and recommended dosing for Phase 2. Evidence of target engagement with prolonged Mcl-1 suppression in peripheral blood cells has been observed in patient samples from the study. &nbsp;We believe that CYC065 is one of the first medicines to demonstrate this in a human trial and look forward to pursuing this lead as part of our transcription regulation program.&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"3255125\" data-linked=\"Cyclacel&#39;s next gen CDK inhibitor CYC065 shows anti-tumor effect in preclinical testing; shares ahead 41%\" data-tweet=\"$CYCC - Cyclacel&#39;s next gen CDK inhibitor CYC065 shows anti-tumor effect in preclinical testing; shares ahead 41% https://seekingalpha.com/news/3255125-cyclacels-next-gen-cdk-inhibitor-cyc065-shows-anti-tumor-effect-in-preclinical-testing-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3255125-cyclacels-next-gen-cdk-inhibitor-cyc065-shows-anti-tumor-effect-in-preclinical-testing-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255126\" data-ts=\"1491230468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIE\" target=\"_blank\">CIE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255126-cobalt-energy-threatens-arbitration-over-angolan-oil-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cobalt Energy threatens arbitration over Angolan oil assets</a></h4><ul>     <li>Cobalt Energy (<a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a> <font color='red'>-4.4%</font>) says it <a href=\"http://www.reuters.com/article/us-angola-oil-cobalt-idUSKBN17513K\" target=\"_blank\">will seek arbitration</a> if Angola's state-run Sonangol fails to extend license deadlines on two offshore blocks, a move it says is needed to help it sell the assets.</li>     <li>CIE, which has been trying to sell the blocks for several years, says its efforts to find a buyer for its 40% stakes have been \"negatively impacted by the uncertainty surrounding the extension.\"</li>     <li>Although Cobalt owns 40% and Sonangol has 30%, the Angolan company holds the rights to extend exploration deadlines for production sharing agreements; <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> owns the remaining 30%.</li>     <li>A deal to sell the licenses to Sonangol in a $1.75B deal collapsed in 2016 because required approvals from the Angolan government did not come in time.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255126\" data-linked=\"Cobalt Energy threatens arbitration over Angolan oil assets\" data-tweet=\"$CIE $CIE $BP - Cobalt Energy threatens arbitration over Angolan oil assets https://seekingalpha.com/news/3255126-cobalt-energy-threatens-arbitration-over-angolan-oil-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3255126-cobalt-energy-threatens-arbitration-over-angolan-oil-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255094\" data-ts=\"1491227934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KITE\" target=\"_blank\">KITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255094-kite-pharma-up-5-on-presentation-of-data-from-phase-1-2-study-of-lead-product-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kite Pharma up 5% on presentation of more data from Phase 1/2 study of lead product candidate axicabtagene ciloleucel</a></h4><ul><li>Kite Pharma (<a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+5.2%</font>) jumps out the blocks on the heels of its announcement of <a href=\"https://seekingalpha.com/pr/16787609-kite-presents-ongoing-response-rate-plenary-session-pivotal-car-t-trial-axicabtagene\" target=\"_blank\">additional positive data</a> from the ZUMA-1 study assessing axicabtagene ciloleucel in patients with advanced blood cancers. The results, first reported in December 2016, were presented at the American Association of Cancer Research Annual Meeting in Washington, DC.</li><li>The study met its primary endpoint of demonstrating a statistically valid objective response rate (82%)(p&lt;0.0001) after a single infusion of axicabtagene ciloleucel. The complete response rate was 54% (36% at month 6). With a median follow-up period of 8.7 months, median overall survival has not been reached.</li><li>The company completed its rolling BLA submission to the FDA last week.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3228875-kite-pharmas-lead-product-candidate-shows-high-response-rate-treatment-resistant-nhl-two\" target=\"_blank\">Kite Pharma's lead product candidate shows high response rate in treatment-resistant NHL, two treatment-related death reported; shares off 4%</a> (Dec. 6, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3255094\" data-linked=\"Kite Pharma up 5% on presentation of more data from Phase 1/2 study of lead product candidate axicabtagene ciloleucel\" data-tweet=\"$KITE - Kite Pharma up 5% on presentation of more data from Phase 1/2 study of lead product candidate axicabtagene ciloleucel https://seekingalpha.com/news/3255094-kite-pharma-up-5-on-presentation-of-data-from-phase-1-2-study-of-lead-product-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3255094-kite-pharma-up-5-on-presentation-of-data-from-phase-1-2-study-of-lead-product-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255095\" data-ts=\"1491227338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255095-dryships-enters-share-purchase-agreement-kalani-investments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips enters share purchase agreement with Kalani Investments</a></h4><ul>     <li>DryShips (<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-18.8%</font>)&nbsp;enters into an agreement with Kalani Investments Limited to sell up to $226.4M of its common stock to the company over a period of 24 months, subject to certain limitations.</li>     <li>DrySDhips expects to use the proceeds from the sales for general corporate purposes.</li>     <li>In addition, DryShips has entered into agreements to acquire six vessels (one Aframax tanker, three Kamsarmax drybulk vessels, two very large gas carriers )for a total gross price of $268M.</li>     <li>\"We are very pleased to announce the acquisition of six more vessels since the beginning of our transformation project that started at the end of last year. In the last three months,\" says CEO George Economou.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16788399-dryships-inc-enters-226_4-million-common-stock-purchase-agreement-kalani-investments-limited\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3255095\" data-linked=\"DryShips enters share purchase agreement with Kalani Investments\" data-tweet=\"$DRYS - DryShips enters share purchase agreement with Kalani Investments https://seekingalpha.com/news/3255095-dryships-enters-share-purchase-agreement-kalani-investments?source=tweet\" data-url=\"https://seekingalpha.com/news/3255095-dryships-enters-share-purchase-agreement-kalani-investments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255092\" data-ts=\"1491226968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXR\" target=\"_blank\">EXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255092-extra-space-storage-up-1-evercore-sees-value\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Extra Space Storage up 1% as Evercore sees value</a></h4><ul><li>After coming in as the worst-performing self-storage name in Q1, the negatives are baked into the stock, says Evercore ISI's Steve Sakwa, upgrading to Inline from Underperform.</li><li><a href='https://seekingalpha.com/symbol/EXR' title='Extra Space Storage, Inc.'>EXR</a>&nbsp;<font color='green'>+0.9%</font>&nbsp;in early action, and now&nbsp;<font color='red'>down 3%</font>&nbsp;for the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255092\" data-linked=\"Extra Space Storage up 1% as Evercore sees value\" data-tweet=\"$EXR - Extra Space Storage up 1% as Evercore sees value https://seekingalpha.com/news/3255092-extra-space-storage-up-1-evercore-sees-value?source=tweet\" data-url=\"https://seekingalpha.com/news/3255092-extra-space-storage-up-1-evercore-sees-value\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255079\" data-ts=\"1491226188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STDY\" target=\"_blank\">STDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255079-steadymed-prevails-in-challenge-to-united-therapeutics-patents-covering-remodulin-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SteadyMed prevails in challenge to United Therapeutics&#39; patents covering Remodulin; shares up 40% premarket; UTHR down 11%</a></h4><ul><li>Ultra-thinly traded micro cap SteadyMed (NASDAQ:<a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a>) jumps&nbsp;<font color='green'>40%</font>&nbsp;premarket on robust volume in response to the <a href=\"https://seekingalpha.com/pr/16788001-cardiomes-partner-steadymed-receives-favourable-ruling-uspto-inter-partes-review\" target=\"_blank\">news </a>that the USPTO's Patent Trial and Appeal Board &#40;PTAB&#41; found that all 22 claims of United Therapeutics' U.S. Patent No. 8,497,393 ('393 patent) covering Remodulin (treprostinil) are unpatentable.</li><li>The '393 patent covers a process to further purify prostacyclin derivatives, such as treprostinil, the active ingredient in Remodulin and SteadyMed's lead product candidate Trevyent.</li><li>SteadyMed expects to file an NDA with the FDA this quarter. Collaboration partner Cardiome (CRME) should file its marketing application in Europe later this year.</li><li>UTHR is off&nbsp;<font color='red'>11%</font>&nbsp;on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255079\" data-linked=\"SteadyMed prevails in challenge to United Therapeutics&#39; patents covering Remodulin; shares up 40% premarket; UTHR down 11%\" data-tweet=\"$STDY $STDY $CORV - SteadyMed prevails in challenge to United Therapeutics&#39; patents covering Remodulin; shares up 40% premarket; UTHR down 11% https://seekingalpha.com/news/3255079-steadymed-prevails-in-challenge-to-united-therapeutics-patents-covering-remodulin-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3255079-steadymed-prevails-in-challenge-to-united-therapeutics-patents-covering-remodulin-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255075\" data-ts=\"1491225870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255075-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/NVCR' title='NovoCure'>NVCR</a> <font color='green'>+67%&nbsp;</font>on positive data from combination therapy.</li>     <li><a href='https://seekingalpha.com/symbol/STDY' title='SteadyMed'>STDY</a> <font color='green'>+36%&nbsp;</font>on favorable patent ruling.</li>     <li><a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='green'>+15%&nbsp;</font>on grant of patent notice in EU.</li>     <li><a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+13% </font>on PDUFA date for HEPLISAV-B remains unchanged.</li>     <li><a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+11% </font>on updates of Phase 1 data for IPI-549 at the AACR 2017.</li>     <li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+10%&nbsp;</font>on European Patent Approval For Underlying Technology of its ThyraMIR microRNA Classifier.</li>     <li><a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+9%&nbsp;</font>on Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response.</li>     <li><a href='https://seekingalpha.com/symbol/ARTX' title='Arotech Corporation'>ARTX</a> <font color='green'>+8% </font>on receiving a sole source follow-on contract to support the U.S. Army&rsquo;s Virtual Clearance Training Suite program.</li>     <li><a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='green'>+8%</font>.</li>     <li>EBIO <font color='green'>+7%&nbsp;</font>on new preclinical data.</li>     <li><a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='green'>+6% </font>on receiving approval for Mundesine in Japan.</li>     <li><a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+6%.&nbsp;</font></li>     <li><a href='https://seekingalpha.com/symbol/ELOS' title='Syneron Medical Ltd.'>ELOS</a> <font color='green'>+5% </font>on acquisition by funds advised by Apax Partners for $11 per share in cash.</li> <li><a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+5%&nbsp;</font>ongoing response rate in plenary session from its pivotal CAR-T trial.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255075\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$NVCR $STDY $APOP - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3255075-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3255075-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255070\" data-ts=\"1491225427\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255070-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise'>HPE</a> <font color='red'>-23%</font>&nbsp;on trimming 2017 outlook.</li><li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='red'>-9%</font>&nbsp;on fiscal earnings.</li><li><a href='https://seekingalpha.com/symbol/UTHR' title='United Therapeutics Corporation'>UTHR</a> <font color='red'>-9%</font>&nbsp;on delaying launch of Remodulin infusion pump.</li><li><a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3255070\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$HPE $MBRX $UTHR - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3255070-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3255070-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255061\" data-ts=\"1491224212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVCR\" target=\"_blank\">NVCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255061-novocures-optune-added-to-chemo-extends-long-term-survival-in-brain-cancer-patients-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novocure&#39;s Optune added to chemo extends long-term survival in brain cancer patients; shares ahead 66% premarket</a></h4><ul><li>Thinly traded Novocure (NASDAQ:<a href='https://seekingalpha.com/symbol/NVCR' title='NovoCure'>NVCR</a>) jumps&nbsp;<font color='green'>66%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16787589-combination-optune-standard-care-chemotherapy-temozolomide-provides-landmark-five-year\" target=\"_blank\">announcement </a>of positive long-term data from a 695-subject Phase 3 clinical trial, EF-14, assessing Optune added to standard chemotherapy temozolomide in newly diagnosed glioblastoma &#40;GBM&#41;&nbsp;patients.</li><li>The two-year survival rate increased to 43% from 30% in patients treated with Optune plus chemo compared to chemo alone. The five-year survival increased to 13% from 5%. The company says these are the best results reported for newly diagnosed GBM patients in a late-stage study. (hazard ratio = 0.63; p&lt;0.00006).</li><li><a href=\"http://www.optune.com/therapy/how-therapy-works.aspx\" target=\"_blank\">Optune&nbsp;</a>is a non-invasive device that creates alternating \"wave-like\" electric fields called Tumor Treating Fields (TTFields). It delivers its therapy to brain tumors through four transducer arrays placed on the scalp.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255061\" data-linked=\"Novocure&#39;s Optune added to chemo extends long-term survival in brain cancer patients; shares ahead 66% premarket\" data-tweet=\"$NVCR - Novocure&#39;s Optune added to chemo extends long-term survival in brain cancer patients; shares ahead 66% premarket https://seekingalpha.com/news/3255061-novocures-optune-added-to-chemo-extends-long-term-survival-in-brain-cancer-patients-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3255061-novocures-optune-added-to-chemo-extends-long-term-survival-in-brain-cancer-patients-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255054\" data-ts=\"1491223474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPTX\" target=\"_blank\">LPTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255054-leap-therapeutics-reports-fy16-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leap Therapeutics reports FY16 results</a></h4><ul><li>Leap Therapeutics (<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics'>LPTX</a>) <a href=\"https://seekingalpha.com/pr/16787368-leap-therapeutics-reports-full-year-2016-financial-results-progression-free-survival-data\" target=\"_blank\">FY16 results</a>: Revenues: $0; R&amp;D Expense: $23.3M (+124.0%); SG&amp;A: $4.2M (+180.0%); Operating Loss: ($27.5M) (-131.1%); Net Loss: ($25.6M) (-111.6%); Quick Assets: $0.8M (+100.0%).</li><li>No guidance given.</li><li>Shares are up&nbsp;<font color='green'>1.9%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255054\" data-linked=\"Leap Therapeutics reports FY16 results\" data-tweet=\"$LPTX - Leap Therapeutics reports FY16 results https://seekingalpha.com/news/3255054-leap-therapeutics-reports-fy16-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3255054-leap-therapeutics-reports-fy16-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255053\" data-ts=\"1491223390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCS\" target=\"_blank\">ONCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255053-oncosecs-ilminus-12-construct-shows-positive-effect-in-preclinical-testing-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoSec&#39;s IL-12 construct shows positive effect in preclinical testing; shares ahead 8% premarket</a></h4><ul><li>Nano cap OncoSec Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a>) perks up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16788056-oncosec-presents-preclinical-data-demonstrating-improved-systemic-anti-tumor-response\" target=\"_blank\">announcement </a>of positive preclinical data on its interleukin-12 (IL-12) construct. In a mouse model of melanoma, the company demonstrated that the changes it made to the plasmid design and electroporation parameters significantly increased IL-12 production leading to an anti-tumor effect. It says the new construct will be the backbone of its next-generation combination molecules.</li><li>The data are being presented today at the American Association of Cancer Research Annual Meeting in Washington, DC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255053\" data-linked=\"OncoSec&#39;s IL-12 construct shows positive effect in preclinical testing; shares ahead 8% premarket\" data-tweet=\"$ONCS - OncoSec&#39;s IL-12 construct shows positive effect in preclinical testing; shares ahead 8% premarket https://seekingalpha.com/news/3255053-oncosecs-ilminus-12-construct-shows-positive-effect-in-preclinical-testing-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3255053-oncosecs-ilminus-12-construct-shows-positive-effect-in-preclinical-testing-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255046\" data-ts=\"1491222853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACN\" target=\"_blank\">ACN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255046-oracle-rejects-accenture-buyout-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle rejects Accenture buyout speculation</a></h4><ul>     <li>Accenture (NYSE:<a href='https://seekingalpha.com/symbol/ACN' title='Accenture plc'>ACN</a>) <font color='red'>-2.3%</font> premarket after Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) rejects a media report claiming it was exploring an acquisition of the company, telling <em>Fortune</em> that it \"<a href=\"http://fortune.com/2017/04/01/oracle-accenture/\" target=\"_blank\">never even considered it</a>.\"</li>     <li>An ORCL spokesperson initially declined comment on Saturday but sent <em>Fortune</em> a categorical denial via email on Sunday.</li>     <li>Speculation swirled <a href=\"https://seekingalpha.com/news/3254224-analysts-turn-skeptical-eye-oracle-accenture-buyout-speculation\" target=\"_blank\">last week</a> that ORCL had hired consultants to look into a possible deal for ACN; such a deal would be a lot to swallow, as ACN has a market cap of more than $74B and trailing 12-month revenues of $33.7B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3255046\" data-linked=\"Oracle rejects Accenture buyout speculation\" data-tweet=\"$ACN $ACN $ORCL - Oracle rejects Accenture buyout speculation https://seekingalpha.com/news/3255046-oracle-rejects-accenture-buyout-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3255046-oracle-rejects-accenture-buyout-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255034\" data-ts=\"1491221135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNGA\" target=\"_blank\">MNGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255034-magnegas-reports-50-revenue-increase-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MagneGas reports 50% revenue increase in Q4</a></h4><ul><li>Revenue for the three months ending December 31, 2016 increased 50% to $2.5M compared to the same period last year.</li><li>FY net loss was $17M, or -$0.35 per share vs.  $9.8M, or -$0.25 a year earlier.</li><li><a href=\"http://ir.stockpr.com/magnegas/press-releases/detail/2556/magnegas-reports-50-increase-in-revenue-for-the-fourth\" target=\"_blank\">Conference call</a> today at 4:00 p.m. ET.</li><li>After <font color='green'>rising 2%</font>, <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> shares are now <font color='red'>down 7%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255034\" data-linked=\"MagneGas reports 50% revenue increase in Q4\" data-tweet=\"$MNGA $TRNX - MagneGas reports 50% revenue increase in Q4 https://seekingalpha.com/news/3255034-magnegas-reports-50-revenue-increase-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3255034-magnegas-reports-50-revenue-increase-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255033\" data-ts=\"1491221128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPE\" target=\"_blank\">HPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255033-hewlett-packard-enterprise-completes-es-spinoff-trims-earnings-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hewlett Packard Enterprise completes ES spinoff, trims earnings outlook</a></h4><ul><li>Hewlett Packard Enterprise (NYSE:<a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise'>HPE</a>)&nbsp;<font color='green'>+2.4%</font> premarket after <a href=\"https://seekingalpha.com/pr/16787922-hewlett-packard-enterprise-completes-spin-merger-enterprise-services-business-csc\" target=\"_blank\">adjusting its Q2 and FY 2017 earnings outlook</a> after completing the spinoff of its Enterprise Services  business and merging it with Computer  Sciences Corp. to create DXC&nbsp;Technology.</li><li>With the partial-year  contribution from Enterprise Services no longer contributing to its financials,  HPE now expects Q2 adjusted EPS  of $0.33-$0.37, down from its prior outlook of $0.41-$0.45, and sees full-year EPS of $1.46-$1.56, down from its previous forecast of $1.88-$1.98; other than the adjustments for the close of the transaction, HPE is maintaining its outlook.</li><li>HPE expects the deal to deliver ~$13.5B in after-tax value to the company and its shareholders.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255033\" data-linked=\"Hewlett Packard Enterprise completes ES spinoff, trims earnings outlook\" data-tweet=\"$HPE - Hewlett Packard Enterprise completes ES spinoff, trims earnings outlook https://seekingalpha.com/news/3255033-hewlett-packard-enterprise-completes-es-spinoff-trims-earnings-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3255033-hewlett-packard-enterprise-completes-es-spinoff-trims-earnings-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255028\" data-ts=\"1491220476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APOP\" target=\"_blank\">APOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255028-cellect-bio-nabs-key-european-patent-covering-engineering-of-immune-cells-for-use-in-treating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellect Bio nabs key European patent covering engineering of immune cells for use in treating immune-related disorders; shares ahead 20% premarket</a></h4><ul><li>Thinly traded nano cap Cellect Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a>) is up&nbsp;<font color='green'>20%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16787745-cellect-receives-notice-intention-grant-european-patent-office-patent-protecting-company-s\" target=\"_blank\">announcement </a>that it has received a formal notice from the European Patent Office of Intention to Grant&nbsp;a patent covering the engineering of regulatory immune cells with enhanced apoptotic activity to be used for immunomodulation in treating or preventing immune-related disorders.</li><li>The patent covers a segment of cell-based therapeutics separate from the one it is currently working in. The company says it may create an opportunity to expand its pipeline.</li><li>The company as awarded the same patent in the U.S. earlier this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255028\" data-linked=\"Cellect Bio nabs key European patent covering engineering of immune cells for use in treating immune-related disorders; shares ahead 20% premarket\" data-tweet=\"$APOP - Cellect Bio nabs key European patent covering engineering of immune cells for use in treating immune-related disorders; shares ahead 20% premarket https://seekingalpha.com/news/3255028-cellect-bio-nabs-key-european-patent-covering-engineering-of-immune-cells-for-use-in-treating?source=tweet\" data-url=\"https://seekingalpha.com/news/3255028-cellect-bio-nabs-key-european-patent-covering-engineering-of-immune-cells-for-use-in-treating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255024\" data-ts=\"1491220263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255024-tesla-runs-higher-after-deliveries-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla runs higher after deliveries update</a></h4><ul> <li>Shares of Tesla Motors (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) could threaten to eclipse their 52-week high today after the company reported just over <a href=\"https://seekingalpha.com/news/3254950-tesla-ships-25k-cars-q1-beating-estimates\" target=\"_blank\">25K deliveries</a> in Q1.</li> <li>On Wall Street, Guggenheim is in early with a price target boost on Tesla to $320, while Baird's Ben Kallo says \"25,000 units is the best we could have thought, and people are looking at Model 3 for growth.\"</li> <li>The company hasn't issued a full-year production estimate yet. Down the road, Tesla aims for 500K units produced in 2018.</li> <li>TSLA <font color='green'>+2.92%</font> premarket to $286.43 vs. a 52-week high of $287.39.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3255024\" data-linked=\"Tesla runs higher after deliveries update\" data-tweet=\"$TSLA - Tesla runs higher after deliveries update https://seekingalpha.com/news/3255024-tesla-runs-higher-after-deliveries-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3255024-tesla-runs-higher-after-deliveries-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>64&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255003\" data-ts=\"1491218722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELOS\" target=\"_blank\">ELOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255003-syneron-candela-sold-for-nearly-400m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syneron Candela sold for nearly $400M</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16787795-syneron-candela-announces-agreement-acquired-funds-advised-apax-partners-11_00-share-cash\" target=\"_blank\">all-cash buyer is</a> P-E player Apax Partners, and the price works out to $11 per share vs. Friday's close of $10.55. The price is a 33% premium to the area Syneron traded in prior to Feb. 10 media speculation of a sale.</li><li>The agreement includes a go-shop period ending on May 9.</li><li><a href='https://seekingalpha.com/symbol/ELOS' title='Syneron Medical Ltd.'>ELOS</a> is&nbsp;<font color='green'>higher by 18.5%</font>&nbsp;to $12.50 per share, suggesting either some believe a bidding war is coming, or just very thin premarket action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3255003\" data-linked=\"Syneron Candela sold for nearly $400M\" data-tweet=\"$ELOS - Syneron Candela sold for nearly $400M https://seekingalpha.com/news/3255003-syneron-candela-sold-for-nearly-400m?source=tweet\" data-url=\"https://seekingalpha.com/news/3255003-syneron-candela-sold-for-nearly-400m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254999\" data-ts=\"1491218599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTNB\" target=\"_blank\">MTNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254999-matinas-biopharma-reports-fy16-results-shares-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matinas Biopharma reports FY16 results; shares up 8% premarket</a></h4><ul>     <li>Matinas Biopharma Holdings (<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a> <font color='green'>+0.7%</font>) <a href=\"https://seekingalpha.com/pr/16787862-matinas-biopharma-reports-2016-financial-results-provides-corporate-update\" target=\"_blank\">FY16 results</a>: Revenues: $0; R&amp;D Expense: $3.9M (-26.4%); SG&amp;A: $4.3M (-10.4%); Operating Loss: ($8.3M) (+16.2%); Net Loss: ($7.6M) (+16.5%); Loss Per Share: ($0.21) (-16.7%); Quick Assets: $4.1M (+28.1%).</li>     <li>No guidance given.</li>     <li>Shares are up&nbsp;<font color='green'>8.3%</font>&nbsp;premarket.</li>     <li>See important <a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254999\" data-linked=\"Matinas Biopharma reports FY16 results; shares up 8% premarket\" data-tweet=\"$MTNB - Matinas Biopharma reports FY16 results; shares up 8% premarket https://seekingalpha.com/news/3254999-matinas-biopharma-reports-fy16-results-shares-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3254999-matinas-biopharma-reports-fy16-results-shares-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3255000\" data-ts=\"1491218590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTHR\" target=\"_blank\">UTHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3255000-united-therapeutics-launch-of-remodulin-implantable-infusion-pump-delayed-until-next-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Therapeutics&#39; launch of Remodulin implantable infusion pump delayed until next year</a></h4><ul><li>United Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/UTHR' title='United Therapeutics Corporation'>UTHR</a>) <a href=\"https://seekingalpha.com/pr/16787715-united-therapeutics-announces-regulatory-delays-remosynch-implantable-pump\" target=\"_blank\">announces </a>that the U.S. commercial launch of RemoSynch, Medtronic's (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) implantable infusion pump for top seller Remodulin (treprostinil), will be delayed until 2018. The device was expected to launch this year.</li><li>The problem appears to be priming bolus issue which Medtronic says it will fix with a software update. The delay is a negative for UTHR since Remodulin will face generic competition next year.</li><li>Management will host a conference call this morning at 9:00 am ET to discuss the situation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3251091-united-therapeutics-3-percent-possible-delay-remodulin-infusion-pump\" target=\"_blank\">United Therapeutics down 3% over possible delay in Remodulin infusion pump</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3255000\" data-linked=\"United Therapeutics&#39; launch of Remodulin implantable infusion pump delayed until next year\" data-tweet=\"$UTHR $UTHR $MDT - United Therapeutics&#39; launch of Remodulin implantable infusion pump delayed until next year https://seekingalpha.com/news/3255000-united-therapeutics-launch-of-remodulin-implantable-infusion-pump-delayed-until-next-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3255000-united-therapeutics-launch-of-remodulin-implantable-infusion-pump-delayed-until-next-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254996\" data-ts=\"1491217988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBKR\" target=\"_blank\">IBKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254996-interactive-brokersminus-1_6-on-wells-fargo-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interactive Brokers -1.6% on Wells Fargo downgrade</a></h4><ul><li>A rare Street sell recommendation comes for Interactive Brokers (IEX:<a href='https://seekingalpha.com/symbol/IBKR' title='Interactive Brokers Group, Inc.'>IBKR</a>) as Wells Fargo's Chris Harris downgrades to Underperform from Market Perform.</li><li>Prior, the stock had three buys and four holds.</li><li>Shares -<font color='red'>1.6</font>% premarket, -<font color='red'>13.2%</font>&nbsp;Y/Y.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254996\" data-linked=\"Interactive Brokers -1.6% on Wells Fargo downgrade\" data-tweet=\"$IBKR - Interactive Brokers -1.6% on Wells Fargo downgrade https://seekingalpha.com/news/3254996-interactive-brokersminus-1_6-on-wells-fargo-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3254996-interactive-brokersminus-1_6-on-wells-fargo-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254994\" data-ts=\"1491217714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVAX\" target=\"_blank\">DVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254994-ad-comm-review-set-for-dynavaxs-heplisav-b-shares-ahead-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Comm review set for Dynavax&#39;s HEPLISAV-B; shares ahead 17% premarket</a></h4><ul><li>Dynavax (NASDAQ:<a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a>) is up&nbsp;<font color='green'>17%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16787713-dynavax-announces-fda-advisory-committee-meeting-review-heplisav-b\" target=\"_blank\">announcement </a>that the FDA's Vaccines and Related Biological Products Advisory Committee will review its marketing application for hepatitis B vaccine candidate HEPLISAV-B on July 28.</li><li>The agency's action date &#40;PDUFA&#41; remains unchanged on August 10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254994\" data-linked=\"Ad Comm review set for Dynavax&#39;s HEPLISAV-B; shares ahead 17% premarket\" data-tweet=\"$DVAX - Ad Comm review set for Dynavax&#39;s HEPLISAV-B; shares ahead 17% premarket https://seekingalpha.com/news/3254994-ad-comm-review-set-for-dynavaxs-heplisav-b-shares-ahead-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3254994-ad-comm-review-set-for-dynavaxs-heplisav-b-shares-ahead-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254987\" data-ts=\"1491217262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCY\" target=\"_blank\">ONCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254987-oncolytics-biotechs-reolysin-shows-treatment-effect-in-mid-stage-breast-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oncolytics Biotech&#39;s REOLYSIN shows treatment effect in mid-stage breast cancer study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16787337-oncolytics-biotech-inc-s-reolysin-provides-statistically-significant-improvement-overall\" target=\"_blank\">Results </a>from an open-label 74-subject study in Canada assessing the combination of Oncolytics Biotech's (ONCYF) REOLYSIN (reovirus variant) and the chemo agent paclitaxel compared to paclitaxel alone in patients with advanced/metastatic breast cancer showed a treatment benefit. Specifically, patients receiving the combination experienced an increase in median overall survival &#40;OS&#41; from 10.4 months to 17.4 months with a 35% reduction in risk (hazard ratio = 0.65). The data are being presented at the American Academy of Cancer Research Annual Meeting in Washington, DC.</li><li>Shares in the thinly traded nano cap firm have doubled since mid-February.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254987\" data-linked=\"Oncolytics Biotech&#39;s REOLYSIN shows treatment effect in mid-stage breast cancer study\" data-tweet=\"$ONCY - Oncolytics Biotech&#39;s REOLYSIN shows treatment effect in mid-stage breast cancer study https://seekingalpha.com/news/3254987-oncolytics-biotechs-reolysin-shows-treatment-effect-in-mid-stage-breast-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3254987-oncolytics-biotechs-reolysin-shows-treatment-effect-in-mid-stage-breast-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254975\" data-ts=\"1491215112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMGTY\" target=\"_blank\">IMGTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254975-imagination-tech-plunges-after-apple-blow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imagination Tech plunges after Apple blow</a></h4><ul><li>Shares in Imagination Tech (<a href='https://seekingalpha.com/symbol/IMGTY' title='Imagination Technology Group PLC ADR'>OTC:IMGTY</a>) <font color='red'>crashed almost 70%</font> in London <a href=\"https://www.thestreet.com/story/14069298/1/apple-dumps-imagination-technologies-shares-plunge-to-8-year-low.html\" target=\"_blank\">after</a> its biggest customer Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) said it would stop using the firm's graphics technology within two years' time.</li><li>\"Apple has asserted that it has been working on a separate, independent graphics design in order to control its products,\" the company said in a statement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254975\" data-linked=\"Imagination Tech plunges after Apple blow\" data-tweet=\"$IMGTY $IMGTY $AAPL - Imagination Tech plunges after Apple blow https://seekingalpha.com/news/3254975-imagination-tech-plunges-after-apple-blow?source=tweet\" data-url=\"https://seekingalpha.com/news/3254975-imagination-tech-plunges-after-apple-blow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254955\" data-ts=\"1491203124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSYY\" target=\"_blank\">TOSYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254955-toshiba-may-miss-another-earnings-deadline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toshiba may miss another earnings deadline</a></h4><ul><li>Toshiba (<a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) shares <font color='red'>fell as much as 9.4%</font> overnight after the struggling conglomerate <a href=\"https://www.bloomberg.com/news/articles/2017-04-03/toshiba-shares-decline-on-risk-of-another-earnings-delay\" target=\"_blank\">signaled</a> it may miss a third deadline to release results for the last quarter of 2016.</li><li>The company will be able to apply to the Tokyo Stock Exchange for another extension, but it could impact its review of Toshiba's qualifications for remaining listed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254955\" data-linked=\"Toshiba may miss another earnings deadline\" data-tweet=\"$TOSYY $TOSBF - Toshiba may miss another earnings deadline https://seekingalpha.com/news/3254955-toshiba-may-miss-another-earnings-deadline?source=tweet\" data-url=\"https://seekingalpha.com/news/3254955-toshiba-may-miss-another-earnings-deadline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":54,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}